In 2012, UCSD (University of California San Diego, Moores Cancer Center, together with Medolife Corp.) conducted research using polarized dilute Blue Scorpion venom utilizing the Mikaelian patented process # US 8097284 B2. The results demonstrated up to 95% apoptotic (programmed cell death) effect in a variety of cancer cell lines incubated for 48 hours, and showed a binding preference to cancer cells only while not affecting normal cells. Additionally, the study showed a synergistic effect with traditional chemotherapy treatments. Research anticipates that PetLife’s Escozine for Pets™ will also extend the life of pets suffering from cancer and improve their quality of life.